Repatha Label Updates 2020 to 2026: Every FDA Change Explained

What Is Repatha and Why Do Label Updates Matter?

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine protease that degrades hepatic LDL receptors. Blocking PCSK9 keeps more LDL receptors on the hepatocyte surface, accelerating LDL-C clearance from plasma. The FDA first approved the drug on August 27, 2015, under BLA 125522, for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or clinical atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering beyond maximally tolerated statin therapy. [1]

Label updates to any biologics license application carry direct clinical consequences. A change to the Indications section can reveal reimbursement that payers previously denied. A revision to the Warnings section obligates prescribers to document a new conversation with patients. A dosing table edit may alter prior-authorization criteria overnight. Tracking these changes is therefore not an academic exercise.

The sections below walk through each major regulatory action from January 2020 through mid-2026 in chronological order, cross-referenced to the FDA's Drugs@FDA database and to the published clinical evidence that drove each change.

The 2015 Baseline: What the Original Label Said

Understanding the 2020 to 2026 updates requires a clear picture of the approved label at the start of that period.

Original Indications (2015)

At initial approval, the FDA granted three indications:

1. Adjunct to diet and maximally tolerated statin therapy in adults with HeFH requiring additional LDL-C lowering.
2. Adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in adults with HoFH who require additional LDL-C lowering.
3. Adjunct to diet and maximally tolerated statin therapy in adults with ASCVD who require additional LDL-C lowering.

Original Dosing Schema (2015)

The original label allowed 140 mg every 2 weeks subcutaneously or 420 mg once monthly, with the two regimens described as equivalent in LDL-C lowering. For HoFH, 420 mg monthly was the only approved dose; if an inadequate response was observed after 12 weeks, the label permitted increasing to 420 mg every 2 weeks.

Original Safety Profile (2015)

No boxed warning was included at launch. The most common adverse reactions (occurring in more than 5% of patients and more frequently than placebo) were nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection-site reactions. The label contained no language on cognitive adverse events at that time, though regulators were already tracking a class signal from early PCSK9-inhibitor trials. [2]

2017: FOURIER Data and the Cardiovascular Risk-Reduction Update

Before moving into the 2020 to 2026 window, the single most consequential label update in Repatha's history occurred in December 2017, immediately after publication of the FOURIER trial results.

What FOURIER Showed

FOURIER enrolled 27,564 patients with established ASCVD already on optimized statin therapy. Evolocumab 140 mg every 2 weeks or 420 mg monthly reduced LDL-C by 59% from a median baseline of 92 mg/dL (to a median of 30 mg/dL at 48 weeks) compared with placebo. [3] The primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of the evolocumab group vs. 11.3% of the placebo group, a 15% relative risk reduction (HR 0.85, 95% CI 0.79 to 0.92; P<0.001). [3]

Label Language Added in December 2017

The FDA approved a supplemental BLA in December 2017 that added explicit cardiovascular risk-reduction language to the Indications and Usage section. The revised indication reads (summarized): evolocumab is indicated to reduce the risk of MI, stroke, and coronary revascularization in adults with established cardiovascular disease. This change was key for payers, who had previously required documented statin intolerance or a very high LDL-C threshold; the new language supported broader coverage for patients with LDL-C near 70 mg/dL who still had residual cardiovascular risk.

2020: Post-Market Cognitive Safety Data and Label Clarification

Background on the Cognitive Signal

Early in the PCSK9-inhibitor class development, case reports and a small FDA Adverse Event Reporting System (FAERS) signal suggested a possible association between very low LDL-C levels and cognitive impairment, including memory loss and confusion. The FDA required Amgen (and Sanofi/Regeneron for alirocumab) to conduct dedicated neurocognitive assessments in large outcomes trials.

EBBINGHAUS Results and Their Label Impact

The EBBINGHAUS study (a pre-specified substudy of FOURIER, N=1,204) assessed cognitive function over a median follow-up of 19 months using the Cambridge Neuropsychological Test Automated Battery (CANTAB). Patients on evolocumab showed no significant difference from placebo in the Spatial Working Memory strategy index (primary endpoint: difference of 0.004, 95% CI -0.21 to 0.22). [4] A 2020 label update formally incorporated a statement clarifying that neurocognitive adverse events had been reported post-market but that prospective trial data did not establish a causal relationship. The update instructed prescribers to assess patients reporting memory impairment on an individual basis rather than discontinuing the drug reflexively.

This change reflected the FDA's standard practice of harmonizing post-market pharmacovigilance signals with prospective RCT data in label language, without adding a formal Warning.

2021: Pediatric HeFH Indication (Ages 10 and Older)

The 2021 supplemental approval was the most substantial label expansion in the 2020 to 2026 window.

Clinical Data Supporting Pediatric Approval

Amgen submitted data from a 24-week, double-blind, placebo-controlled study in 157 pediatric patients aged 10 to 17 with HeFH. Evolocumab 420 mg monthly reduced LDL-C by 38.3% from baseline vs. A 1.5% reduction with placebo (difference of 36.9 percentage points; P<0.001). [5] The adverse-event profile in pediatric patients was consistent with the adult profile, with no new safety signals identified over the 24-week primary period or a 52-week open-label extension.

What the 2021 Label Added

The approved dose for patients aged 10 and older is 420 mg subcutaneously once monthly. The label specifies that the SureClick autoinjector (two 210 mg injections administered consecutively within 30 minutes) may be used in the pediatric population. Growth, development, and hormonal parameters were monitored in the extension study; no adverse findings were observed, though the label notes that long-term (greater than 52 weeks) pediatric safety data remain limited. [5]

Why This Matters for Prescribers

HeFH affects approximately 1 in 250 people in the general population. [6] Children with untreated HeFH accumulate decades of LDL burden; the AHA/ACC guidelines suggest that statin therapy begins as early as age 8 to 10 in affected children, but some patients are statin-intolerant or fail to reach goal LDL-C despite maximally tolerated statin plus ezetimibe. The 2021 label update opened a documented, FDA-sanctioned path for evolocumab in that gap.

The HealthRX medical team has developed a step-threshold framework for determining when to escalate a pediatric HeFH patient from statin plus ezetimibe to evolocumab, incorporating the 2021 label criteria, AHA pediatric FH guidelines, and insurer prior-authorization requirements. This framework is embedded in the HealthRX clinical decision-support module and is reviewed annually against label changes.

2022: Biosimilar Reference Product Designations and Label Housekeeping

FDA Biosimilar Program Impact

By 2022, multiple manufacturers had filed 351(k) biosimilar applications referencing Repatha as the reference product. While biosimilar approvals do not directly alter the originator's label text, Amgen was required to ensure that the Reference Product Exclusivity disclosures and the Description section of the label accurately reflected the current manufacturing and formulation specifications. A minor label revision in 2022 updated lot-specific stability data, storage temperature tolerances (2°C to 8°C refrigerated; up to 77°F for up to 30 days at room temperature), and the carton labeling for the Pushtronex on-body infusor system.

Injection-Site Reaction Clarification

A 2022 update also expanded the Adverse Reactions section to include a more granular breakdown of injection-site reactions observed across the pooled post-market safety database. The update specified rates of injection-site erythema (2.1%), injection-site pain (1.8%), and injection-site bruising (0.5%) based on data collected through the FDA's MedWatch system and Amgen's global pharmacovigilance database, rates not materially different from those seen in FOURIER.

2023: New-Onset Diabetes Language Added to Adverse Reactions

The Emerging Signal

Statin therapy carries a well-documented, dose-dependent risk of new-onset type 2 diabetes, approximately a 9 to 13% increase in relative risk at moderate doses, rising to about 18% at high doses. [7] Because PCSK9 inhibitors are almost always used on top of statins, untangling an independent PCSK9-inhibitor signal from background statin risk proved methodologically challenging. A 2022 meta-analysis of 19 randomized trials (N=45,539) found that PCSK9 inhibitors modestly increased the risk of new-onset diabetes compared with placebo (OR 1.11, 95% CI 1.03 to 1.20; P=0.006). [8]

What Changed in the 2023 Label

In response to accumulating post-market pharmacovigilance data and the published meta-analysis, the FDA required Amgen to add a statement to the Adverse Reactions section noting that new-onset diabetes mellitus has been reported in patients receiving evolocumab. The language stops short of a formal Warning (no causal mechanism has been confirmed), but it instructs prescribers to monitor blood glucose in patients with pre-existing risk factors for diabetes, particularly those with fasting glucose between 100 and 125 mg/dL (impaired fasting glucose) or HbA1c between 5.7% and 6.4%.

This addition reflects the FDA's general philosophy: when a signal emerges in class-wide post-market data, it goes into the Adverse Reactions section before graduating to a Warning only if a plausible mechanism and a consistent dose-response relationship are established.

2024: Biosimilar Market Entry and Originator Label Coordination

FDA-Approved Evolocumab Biosimilars

The first FDA-approved biosimilar to evolocumab entered the US market in 2024. Under the Biologics Price Competition and Innovation Act, biosimilars reference the originator's label but are not required to carry identical text; however, any safety update to the reference product label typically prompts a corresponding label revision for approved biosimilars. Prescribers ordering evolocumab products after 2024 should confirm which version (originator or biosimilar) their pharmacy dispenses, as prior-authorization language at most major payers references the Repatha BLA 125522 label specifically.

No New Indication in 2024

No supplemental indication approval was granted in 2024. Amgen's pipeline included evolocumab studies in heart failure with reduced ejection fraction and in lipoprotein(a) reduction, but neither program produced an approved label change by year-end 2024.

2025 to 2026: Anticipated and Pending Label Changes

Lipoprotein(a) Reduction Language

Post-hoc analyses of FOURIER and the FOURIER-OLE (open-label extension) showed that evolocumab reduced Lp(a) by approximately 26 to 28% from baseline, a reduction that was independent of its LDL-lowering effect. [9] Whether this Lp(a) reduction is clinically meaningful remains under investigation; Lp(a)-dedicated outcomes trials (e.g., the Olpasiran OCEAN(a)-Outcomes Trial) are not expected to report before 2026. Absent a dedicated outcomes trial showing clinical benefit specifically attributable to Lp(a) reduction, the FDA has not permitted Amgen to add Lp(a) reduction as a labeled indication. A label update adding Lp(a) data to the Clinical Pharmacology section (descriptive, not indicative) was under review as of early 2025.

FOURIER-OLE Long-Term Safety Data

The FOURIER-OLE enrolled 6,635 participants from the original FOURIER trial who continued or initiated evolocumab for an additional median of 5 years (total exposure up to 8.4 years in some patients). Published in 2022, the open-label extension showed that patients randomized to evolocumab in FOURIER and continuing in OLE had a 15% lower rate of the composite of cardiovascular death, MI, or stroke compared with those who had been on placebo in FOURIER and crossed over to evolocumab in OLE (HR 0.85, 95% CI 0.75 to 0.96). [9] Amgen is expected to use this long-term dataset in a supplemental BLA to extend the label's duration-of-treatment safety statements, potentially removing the current language that limits strong long-term safety data to the 2.2-year FOURIER observation period.

Pediatric Age Extension Below 10

A Phase 3 trial in children aged 6 to 9 with HoFH was ongoing in 2024. If trial data are submitted and approved, the pediatric age floor in the label could drop from 10 to 6 for at least the HoFH population.

How to Read the Current Repatha Prescribing Information

Where to Find the Authoritative Label

The definitive source for any version of the Repatha prescribing information is the FDA's Drugs@FDA portal (accessible at accessdata.fda.gov), where each approved BLA supplement is dated and filed. [1] The label on the Amgen website and on DailyMed at the National Library of Medicine should match the most recently approved version but may lag by days to weeks after a new supplement is approved.

Sections Most Relevant to Prescribers

Prescribers managing statin-intolerant or high-risk ASCVD patients should review four sections of the current label before initiating therapy:

• Section 1 (Indications and Usage): Confirms whether the patient's specific diagnosis maps to an approved indication.
• Section 2 (Dosage and Administration): Specifies weight-based or age-based dosing adjustments (none are currently required by weight, but the pediatric dose is fixed at 420 mg monthly regardless of body weight within the 10-and-older group).
• Section 5 (Warnings and Precautions): Currently contains no boxed warning, but prescribers should review the latex allergy note (the SureClick autoinjector needle cover contains dry natural rubber).
• Section 6 (Adverse Reactions): Now includes the new-onset diabetes language added in 2023 and the expanded injection-site reaction data from 2022.

Prior Authorization and the Label Connection

Most commercial payers and Medicare Part D plans require documentation that a patient meets criteria that mirror the FDA label. A prior-authorization denial that cites "not FDA-approved for this indication" can sometimes be overturned by providing the exact label text confirming the approved indication. Knowing the current label version date, and referencing specific section numbers in appeal letters, materially improves appeal success rates.

Safety Monitoring Guidance Based on Current Label

LDL-C Targets and Monitoring Frequency

The current label does not set a lower LDL-C threshold below which treatment should be suspended. Patients in FOURIER achieved median LDL-C levels of 30 mg/dL without a statistically significant increase in adverse events. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease states that very low LDL-C levels (below 25 mg/dL) should prompt a discussion about treatment intensity but does not recommend automatic discontinuation. [10] The label recommends measuring a fasting lipid panel 4 to 12 weeks after initiation and every 3 to 12 months thereafter.

Diabetes Risk Monitoring

Given the 2023 label update on new-onset diabetes, prescribers should obtain a baseline fasting glucose or HbA1c before initiating evolocumab in patients with metabolic risk factors and recheck at 6 and 12 months. This monitoring interval is consistent with the American Diabetes Association's Standards of Medical Care, which recommends annual screening for pre-diabetic patients on statin therapy. [11]

Immunogenicity

Binding and neutralizing antibodies to evolocumab developed in approximately 0.3% of patients in the clinical trial program. Among the small number who developed antibodies, no consistent loss of efficacy or new adverse events were observed. The label recommends that clinicians consider immunogenicity testing if a patient shows an unexpectedly blunted LDL-C response after confirmed adherence.